Who mentions $DNLI most on Surfaced?

@theaiportfolios (The Claude Portfolio) mentions $DNLI most — 3 mentions in the past 12 months.

When was $DNLI first mentioned on Surfaced?

The earliest tracked mention of $DNLI in the Surfaced archive was on Mar 25, 2026.

How many voices track $DNLI?

3 FinTwit voices have mentioned $DNLI 7 times in the past 12 months.

What kind of voices mention $DNLI most?

$DNLI is mentioned most by Software voices on Surfaced.

Last 12mo stats

mentions

voices

$DNLI

Denali Therapeutics Inc

$DNLI

Denali Therapeutics Inc

Past 12mo:7mentions3voices

All voices2 calls since May 2026show all

Loading price chart…

About this stock

$DNLI has been mentioned 7 times over the past 12 months by 3 distinct FinTwit voices, with @theaiportfolios leading at 3 mentions, followed by @adamfeuerstein and @investmentguru_ at 2 mentions each. The first mention appeared on March 25, 2026, and the most recent on July 12, 2026. Discussion has centered on Denali Therapeutics' neurodegenerative disease focus, particularly its Alzheimer's and Parkinson's programs, with particular attention to the company's work on getting drugs across the blood-brain barrier.

AI-generated from tracked posts · updated Jul 14, 2026

Frequently asked

Related stocks

$ALKSAlkermes

$ALMSAlumis

$ASNDAscendis Pharma A/S

$ATAIATAI Life Sciences

Recent calls

2 calls

@theaiportfoliosMay 22, 2026 · 3:00 PM

New Trade: Claude just went gone risk off and moved a new position to 'cash' It took our $50K and sold its Denali Therapeutics $DNLI and opened a new position in short term treasuries $SGOV Here's it's reasoning: "After the close on May 21, Biogen and Denali announced that the LUMA trial failed. The primary endpoint and every secondary endpoint. Both companies are discontinuing idiopathic Parkinson's development entirely. That program was the thesis. I entered Denali (DNLI) on May 4, and the LUMA Phase 2b readout was the headline binary the whole position was built on. Eighteen days later it fired, early and negative. The after-hours move was around 8 percent, which does not begin to reflect what a complete clinical failure means for a small biotech whose valuation upside lived in that one program. My research re-scored the position to a negative 12-month expected return, the only negative one in the book. This was not a bad week. The thesis broke. So I exited DNLI in full at Friday's open. My positions carry a roughly two-month hold floor, with an explicit exception for a broken thesis. This is exactly that case. Holding a position for discipline's sake after the reason you owned it is gone is not discipline, it is stubbornness. Here is the part I want to be honest about. I am not redeploying that capital today. There was a replacement candidate, and on the numbers it scored well. But when I asked the only question that actually matters, would I be comfortable owning this for months, the answer was not a clear yes. So I am not forcing it. The proceeds sit in short-term Treasurys, earning the risk-free rate, while I wait for something that genuinely clears the bar. There is a cluster of binary events over the next few weeks, a Federal Reserve decision in June and live oil-supply headlines among them. Holding a little dry powder into that is optionality, not a cost. I would rather wait a few days than own a position I picked because it was the best of an uninspiring set. The other 14 holdings are unchanged. I take a fresh look at the full opportunity set next week. If something compelling is there, I will move. If not, I will keep waiting." Not advice, just how I am sizing my own book. Updated full positions can be found on Autopilot via the follow up tweet

Open on X

@theaiportfoliosMay 6, 2026 · 2:33 PM

Breaking: Claude just bought another small cap Pharma company Claude took our $50,000 and opened a brand new position in Denali Therapeutics $DNLI It's an earnings play happening later today but here's the reasoning on why they bought: "The immediate catalyst is Wednesday evening's Q1 print. Denali launched AVLAYAH, its enzyme replacement therapy for neurological Hunter syndrome (MPS II), in late March 2026. This earnings call will be the first time management presents commercial launch data publicly: patient starts, payer coverage penetration, and the Lonza manufacturing run-rate. The orphan-disease commercial ramp cadence is the question the market is pricing uncertainly. I think that uncertainty is more favorable than the current share price implies, and the reasoning starts with the competitive picture.REGENXBIO's RGX-121 gene therapy received an FDA Complete Response Letter in February 2026. That CRL effectively leaves AVLAYAH with uncontested US neurologic-Hunter space. There is no approved competing product in this indication. The patient population is roughly 500 in the United States, characteristic of an ultra-rare orphan indication. Pricing at $5,200 per vial puts annual costs between $270K and $811K per patient depending on weight. That pricing sits directly in line with Aldurazyme and Naglazyme, the two most comparable orphan-drug pricing precedents. The research edge on this position came from two specific corrections I made to upstream consensus models. First, AVLAYAH's FDA approval was March 25, 2026, not May 3 as it appeared in several downstream analyses. A wrong approval date would have compressed the commercial launch timeline in any model using it, understating how many commercial weeks the drug has actually had. Second, DNL343, Denali's ALS program, failed a clinical trial in January 2025. It was appearing in multiple consensus inputs as a pending H2 2026 readout, meaning its expected value was being counted in 12-month expected return projections that will never fire. Correcting both errors shifts my base case to a $24.75 price target and +32.6% expected 12-month return. The risks are real: $400 million annual cash burn against $900 million in cash gives roughly a two-year runway, manufacturing scale-up at Lonza is a first commercial product for DNLI, and the orphan population of approximately 500 US patients caps the total addressable ceiling in this indication. The sizing at 4.82% reflects those risks. The position sizes a real bet without overcrowding it. Expected: 1M +7% | 3M +29% | 12M +32.6%"

Open on X